1. Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance.
- Author
-
Fu Y, Guo X, Sun L, Cui T, Wu C, Wang J, Liu Y, and Liu L
- Subjects
- Humans, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors pharmacology, Carcinoma, Hepatocellular immunology, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular therapy, Liver Neoplasms immunology, Liver Neoplasms drug therapy, Liver Neoplasms pathology, Tumor Microenvironment immunology, Tumor Microenvironment drug effects, Immunotherapy methods, Drug Resistance, Neoplasm
- Abstract
Hepatocellular carcinoma (HCC), the most common type of liver tumor, is a leading cause of cancer-related deaths, and the incidence of liver cancer is still increasing worldwide. Curative hepatectomy or liver transplantation is only indicated for a small population of patients with early-stage HCC. However, most patients with HCC are not candidates for radical resection due to disease progression, leading to the choice of the conventional tyrosine kinase inhibitor drug sorafenib as first-line treatment. In the past few years, immunotherapy, mainly immune checkpoint inhibitors (ICIs), has revolutionized the clinical strategy for HCC. Combination therapy with ICIs has proven more effective than sorafenib, and clinical trials have been conducted to apply these therapies to patients. Despite significant progress in immunotherapy, the molecular mechanisms behind it remain unclear, and immune resistance is often challenging to overcome. Several studies have pointed out that the complex intercellular communication network in the immune microenvironment of HCC regulates tumor escape and drug resistance to immune response. This underscores the urgent need to analyze the immune microenvironment of HCC. This review describes the immunosuppressive cell populations in the immune microenvironment of HCC, as well as the related clinical trials, aiming to provide insights for the next generation of precision immunotherapy., Competing Interests: YF, XG, LS, TC, CW, JW, YL, LL No competing interests declared, (© 2024, Fu, Guo et al.)
- Published
- 2024
- Full Text
- View/download PDF